|
|
Henry Schein Inc (NASDAQ: HSIC) |
|
|
|
| |
Henry Schein Inc 's Revenue per Employee
Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales
Henry Schein Inc 's Revenue per employee fell on a trailing twelve month basis to $ 666,789, but the productivity of Henry Schein Inc 's employees remained above the company average. Within the Healthcare sector Employees of 81 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 705, from total ranking in previous quarter at 803. Henry Schein Inc has 19,000 employees.
What is Sales per Employee Ratio?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| HSIC Revenue per Employee |
(Mar 29 2025)
I. Quarter |
(Dec 28 2024)
IV. Quarter |
(Sep 28 2024)
III. Quarter |
(Jun 29 2024)
II. Quarter |
(Mar 30 2024)
I. Quarter |
| Y / Y Revenue Change |
-0.13 % |
5.77 % |
0.38 % |
1.16 % |
3.66 % |
| Sales per Employee (TTM) $ |
666,789 |
667,000 |
657,842 |
657,211 |
655,316 |
| HSIC's Total
Ranking |
# 705 |
# 803 |
# 1014 |
# 718 |
# 743 |
| Seq. Revenue Change |
-0.72 % |
0.54 % |
1.21 % |
-1.13 % |
5.14 % |
| Revenue per Employee Statistics |
| High |
Average |
Low |
| $ 694,842 |
$ 610,612 |
$ 488,999 |
| (Dec 29 2018) |
|
(Jun 27 2020) |
Date modified: 2025-05-06T07:48:28+00:00
| Companies with similar Revenue per Employee for 12 months ending Mar 29 2025, within Healthcare Sector | Revenue per Employee | Revenue 12 months ending Mar 29 2025 | Number of Employees Mar 29 2025 | | Abbvie Inc | 1,147,340.00 | $ 57,367.000 Million | 50,000 | | Eli Lilly And Company | 1,139,609.30 | $ 49,003.200 Million | 43,000 | | Koru Medical Systems Inc | 1,131,733.55 | $ 35.084 Million | 31 | | Biodesix Inc | 1,128,227.27 | $ 74.463 Million | 66 | | Alnylam Pharmaceuticals Inc | 1,118,142.38 | $ 2,348.099 Million | 2,100 | | Apellis Pharmaceuticals Inc | 1,100,480.85 | $ 775.839 Million | 705 | | Sensus Healthcare Inc | 1,089,200.00 | $ 38.122 Million | 35 | | Century Therapeutics inc | 1,073,813.08 | $ 114.898 Million | 107 | | Dynavax Technologies Corporation | 1,071,345.45 | $ 294.620 Million | 275 | | Integrated Biopharma Inc | 1,067,540.00 | $ 53.377 Million | 50 | | Ani Pharmaceuticals Inc | 1,049,950.16 | $ 674.068 Million | 642 | | Regeneron Pharmaceuticals Inc | 1,047,263.94 | $ 14,085.700 Million | 13,450 | | Fulgent Genetics Inc | 1,029,778.17 | $ 292.457 Million | 284 | | Supernus Pharmaceuticals inc | 1,024,535.28 | $ 667.997 Million | 652 | | Ionis Pharmaceuticals Inc | 1,015,257.82 | $ 941.144 Million | 927 | | Lifevantage Corp | 997,864.86 | $ 221.526 Million | 222 | | Electromed Inc | 983,612.90 | $ 60.984 Million | 62 | | Protalix Biotherapeutics inc | 979,737.70 | $ 59.764 Million | 61 | | Blueprint Medicines Corporation | 965,843.64 | $ 562.121 Million | 582 | | Electrocore Inc | 950,370.37 | $ 25.660 Million | 27 | | Vaxart Inc | 929,313.73 | $ 47.395 Million | 51 | | P3 Health Partners Inc | 928,245.00 | $ 1,485.192 Million | 1,600 | | Myomo Inc | 916,569.74 | $ 38.496 Million | 42 | | Ptc Therapeutics inc | 904,550.75 | $ 900.028 Million | 995 | | Lipocine Inc | 900,875.25 | $ 14.414 Million | 16 | | Ligand Pharmaceuticals Incorporated | 897,485.15 | $ 181.292 Million | 202 | | Option Care Health Inc | 892,696.51 | $ 5,185.674 Million | 5,809 | | Eyepoint Pharmaceuticals Inc | 889,555.56 | $ 56.042 Million | 63 | | Merck and Co Inc | 887,805.56 | $ 63,922.000 Million | 72,000 | | Metagenomi Inc | 887,509.80 | $ 45.263 Million | 51 |
|
